{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"84.922","value":"174.00"},{"groupId":"OG001","spread":"196.714","value":"205.63"}]}],"title":"Cmin"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"195.95","value":"546.0"},{"groupId":"OG001","spread":"189.98","value":"711.3"}]}],"title":"Cmax"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points. Pharmacokinetic analysis of Niraparib was conducted using standard non-compartmental analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Niraparib 200 milligrams (mg) orally once daily from Days 1 to 21 and Pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 1: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants received Niraparib 300 mg orally once daily from Days 1 to 21 and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 1: Niraparib 300 mg + Pembrolizumab"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic Analysis Set. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 4, 6, 8, 24 Hours post-dose on Cycle 1 Day 1 (each cycle of 21 days)","title":"Phase 1: Minimum Observed Plasma Concentration (Cmin) and Maximum Observed Plasma Concentration (Cmax) of Niraparib","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}